FDG PET Scanning in Germ Cell Tumours

  • R. A. Huddart
  • S. F. Hain
Conference paper

Abstract

Cross sectional imaging plays a key role (in combination with tumour markers) in the management of men presenting with testicular germ cell tumours (TGCT). The most commonly used imaging modality is computerised tomography (CT) scanning. CT is routinely used in the initial staging of patients, in assessment of disease response and detection of relapse. CT, however, suffers from a number of limitations mainly due to its reliance on structural abnormalities to identify disease. This means CT cannot, for instance, detect disease in ‘normal sized lymph nodes’ or tell whether there is active tumour in residual masses after chemotherapy. These difficulties limit the accuracy of CT in assessing TGCT. A prime example of this is the knowledge that approximately 25 per cent of patients will have normal sized para-aortic nodes containing tumour and a proportion patients with enlarged nodes will not [1, 2].

Keywords

Positron Emission Tomography Standard Uptake Value Germ Cell Tumour Computerise Tomography Testicular Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nichols C. Testicular cancer. Curr Probl Cancer 1998;22:187–274PubMedCrossRefGoogle Scholar
  2. 2.
    Aass N, Fossa S, Ous S et al. Is routine primary retroperitoneal lymph node dissection still justified in patients with low stage non-seminomatous testicular cancer? Br J Urol 1990;65:385–90PubMedCrossRefGoogle Scholar
  3. 3.
    Lewis P, Griffin S, Marsden P et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265–6PubMedCrossRefGoogle Scholar
  4. 4.
    Sazon DA, Santiago SM, Soo Hoo GW et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417–21PubMedGoogle Scholar
  5. 5.
    White P, Adams H, Crane M, Butchart E. Preoperative staging of carcinoma of the bronchus: Can computed tomographic scanning reliably identify stage III tumors? Thorax 1994;49:951–7PubMedCrossRefGoogle Scholar
  6. 6.
    Avril N, Dose J, Janicke F et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)- fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996;88:1204–9PubMedCrossRefGoogle Scholar
  7. 7.
    Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996;23:1588–93PubMedCrossRefGoogle Scholar
  8. 8.
    Steinert HC, Huch Boni RA, Buck A et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705–9PubMedGoogle Scholar
  9. 9.
    Boni R, Boni RA, Steinert H et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995;132:556–62PubMedCrossRefGoogle Scholar
  10. 10.
    Schlepers C, Penninckx F, De Vadder N et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517–22CrossRefGoogle Scholar
  11. 11.
    Delbeke D, Vitola JV, Sandler MP et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196–201PubMedGoogle Scholar
  12. 12.
    Flanagan FL, Dehdashti F, Siegel BA et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 1997;168:417–24Google Scholar
  13. 13.
    Lucas JD, O’Doherty MJ, Wong JC et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas .J Bone Joint Surg Br 1998;80:441–7PubMedCrossRefGoogle Scholar
  14. 14.
    Eary JF, Conrad EU, Bruckner JD et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998;4:1215–20PubMedGoogle Scholar
  15. 15.
    Adler LP, Blair HF, Williams RP et al. Grading liposarcomas with PET using [ 18F] FDG. J Comput Assist Tomogr 1990;14:960–2PubMedCrossRefGoogle Scholar
  16. 16.
    Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22–30PubMedCrossRefGoogle Scholar
  17. 17.
    Romer W, Hanauske AR, Ziegler S et al. Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464–71PubMedGoogle Scholar
  18. 18.
    Cremerius U, Effert PJ, Adam G et al. FDG PET for detection and therapy control of metastatic germ cell tumor.J Nucl Med 1998;39:815–22PubMedGoogle Scholar
  19. 19.
    Stephens A, Gonin R, Hutchins G, Einhorn L. Positron Emission Tomography Evaluation of Residual Radiographic Abnormalities in Postchemotherapy Germ Cell Tumor Patients. J Clin Oncol 1996;14:1637–41PubMedGoogle Scholar
  20. 20.
    Hain S, O’Doherty M, Timothy A, Leslie M, Harper P, Huddart R. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Brit J Cancer 2000;83:863–9PubMedCrossRefGoogle Scholar
  21. 21.
    Sugawara Y, Zasadny K, Grossman H, Francis I, Clarke M, Wahl R. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 1999;211:249–56PubMedGoogle Scholar
  22. 22.
    Cremerius U, Bares R, Weis J et al. Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET J Nucl Med 1997;38:26–30PubMedGoogle Scholar
  23. 23.
    Duchesne GM, Stenning SP, Aass N et al. Radiotherapy after chemotherapy for metastatic seminoma — a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997;33:829–35PubMedCrossRefGoogle Scholar
  24. 24.
    Ganjoo KN, Chan RJ, Sharma M, Einhorn LH. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 1999;17:3457–60PubMedGoogle Scholar
  25. 25.
    Nuutinen JM, Leskinen S, Elomaa I et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 1997;33:1234–41PubMedCrossRefGoogle Scholar
  26. 26.
    Boerner AR, Weckesser M, Herzog H et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999;26:226–30PubMedCrossRefGoogle Scholar
  27. 27.
    Kubota K, Itoh M, Ozaki K et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001;28:696–703PubMedCrossRefGoogle Scholar
  28. 28.
    Hain S, O’Doherty M, Timothy A, Leslie M, Partridge S, Huddart R. Fluorodeoxyglucose (PET) in the initial staging of germ cell tumours. Eur J Nucl Med 2000;27:590–4PubMedCrossRefGoogle Scholar
  29. 29.
    International Germ Cell Consensus Classification. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594–603Google Scholar
  30. 30.
    Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack H-J, Mueller S. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1998;53:808–11CrossRefGoogle Scholar
  31. 31.
    Lassen U, Daugaard G, Rorth M, Eigtved A, Friberg L. Detection of metastatic disease with postron emission tomography negative non-seminomatous ger cell tumors (Abstract No. 1142). Proc Am Soc Clin Oncol 1997;16:321aGoogle Scholar
  32. 32.
    Muller-Mattheis V, Reinhardt M, Gerharz C et al. Positron emission tomography with (18 F)-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors. Urology 1998;37:609–20Google Scholar
  33. 33.
    Wilson CB, Young HE, Ott RJ et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 1995;22:508–13PubMedCrossRefGoogle Scholar
  34. 34.
    Harns W, Bares R, Kamps H et al. Therapy control of metastatic testicular carcinoma with F18-DOG PET. J Nucl Med 1995;Suppl. 36:198PGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2002

Authors and Affiliations

  • R. A. Huddart
    • 1
  • S. F. Hain
    • 1
  1. 1.The Royal Marsden Hospital and. The Institute of Cancer ResearchSuttonUK

Personalised recommendations